natgillin/translations-raw huggingface dataset:
In SC-I, 1262 patients were randomized 1:1 to receive tocilizumab subcutaneous 162 mg every week or tocilizumab intravenous 8 mg/kg every four weeks in combination with non-biologic DMARD(s).
U ispitivanju SC-I, 1262 bolesnika randomizirana su u omjeru 1:1 za liječenje tocilizumabom u supkutanoj dozi od 162 mg jedanput tjedno ili u intravenskoj dozi od 8 mg/kg jedanput svaka 4 tjedna, u kombinaciji s nebiološkim DMARD-ovima.
In SC-I, a total of 625 patients treated with tocilizumab 162mg weekly were tested for anti- tocilizumab antibodies in the 6 month controlled period.
Tijekom 6-mjesečnog kontroliranog razdoblja u ispitivanju SC-I, ukupno je 625 bolesnika liječenih tocilizumabom u dozi od 162 mg jedanput tjedno testirano na protutijela na tocilizumab.
In SC-II, a total of 434 patients treated with tocilizumab 162mg every other week were tested for anti- tocilizumab antibodies in the 6 month controlled period.
Tijekom 6-mjesečnog kontroliranog razdoblja u ispitivanju SC-II, ukupno su 434 bolesnika liječena tocilizumabom u dozi od 162 mg jedanput svaka dva tjedna testirana na protutijela na tocilizumab.
In SCN patients
Bolesnici s teškom kroničnom neutropenijom
In SCN patients
U bolesnika s teškom kroničnom neutropenijom
In SCN patients
U bolesnika sa SCN
In SCN patients the most frequent undesirable effects attributable to filgrastim were bone pain, general musculoskeletal pain and splenomegaly.
U bolesnika s teškom kroničnom neutropenijom najčešće nuspojave koje se mogu povezati s filgrastimom bile su koštana bol, opća mišićno-koštana bol i splenomegalija.
In SCN patients the most frequent undesirable effects attributable to filgrastim were bone pain, general musculoskeletal pain and splenomegaly.
U bolesnika teškom kroničnom neutropenijom, najčešće nuspojave koje su se mogle pripisati filgrastimu bile su koštana bol, opća mišićno-koštana bol i splenomegalija.
In SCN patients, the most frequent undesirable effects attributable to filgrastim were bone pain, general musculoskeletal pain and splenomegaly.
U bolesnika s teškom kroničnom neutropenijom najčešći neželjeni učinci koje se mogu pripisati filgrastimu bile su koštana bol, opća mišićno-koštana bol i splenomegalija.
In secondary analyses on the subset of patients undergoing allogeneic transplants, Defitelio prophylaxis was also associated with a lower incidence and less Grade 2 to 4 severity of acute graft versus host disease (aGvHD) by Day+100.
U sekundarnim analizama na podskupini bolesnika koji su bili podvrgnuti alogenetskim transplantacijama, profilaksa Defiteliom bila je također povezana s nižom incidencijom i nižim stupnjem težine 2 do 4 akutne reakcije presatka protiv domaćina (aGvHD) do dana+100.
In SEGA caused by tuberous sclerosis, Votubia has been studied in two main studies: the first study involved 28 adults and children aged three years and above.
U slučaju SEGA uzrokovanog tuberoznom sklerozom, lijek Votubia ispitan je u dva glavna ispitivanja: prvim ispitivanjem bilo je obuhvaćeno 28 odraslih osoba i djece u dobi od tri godine i starije.
In serial passage with strain NL432-based site directed mutants at N155H or E92Q, no further selection of resistance was seen (fold change unchanged around 1).
U serijskoj pasaži s izolatima na bazi soja NL432 s ciljanom mutagenezom na N155H ili E92Q, nije primijećena daljnja selekcija rezistencije (vrijednost promjene od približno 1 ostala je nepromijenjena).
In serious cases there can be recurrence of vomiting and gastrointestinal bleeding, 12 hours after ingestion.
U teškim slučajevima predoziranja može doći do ponovnog povraćanja i gastrointestinalnog krvarenja 12 sati nakon uzimanja željeza.
In several controlled studies, epoetins have not been shown to improve overall survival or decrease the risk of tumour progression in patients with anaemia associated with cancer.
U nekoliko kontroliranih ispitivanja epoetini nisu pokazali da poboljšavaju opće preživljenje ili smanjuju rizik napredovanja tumora kod bolesnika s anemijom povezanom s malignim bolestima.
In several controlled studies, epoetins have not been shown to improve overall survival or decrease the risk of tumour progression in patients with anaemia associated with cancer.
U nekoliko kontroliranih ispitivanja nije se pokazalo da epoetini poboljšavaju ukupno preživljenje ili smanjenje rizika od progresije tumora u bolesnika s anemijom povezanom s rakom.
In severe aplastic anaemia, 40% of patients (17 out of 43) responded to treatment after 12 weeks, and 65% of responders (11 out of 17) either had a platelet count increase of at least 20,000 cells per microliter or had a platelet count that was stable without need for blood transfusions.
U slučaju teške aplastične anemije 40 % bolesnika (17 od 43) odgovorilo je na terapiju nakon 12 tjedana, a kod 65 % njih (11 od 17) zabilježeno je ili povećanje broja trombocita od najmanje 20 000/µl ili stabilan broj trombocita koji nije zahtijevao transfuziju krvi.
In severe cases the following symptoms may occur: unreality, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations or epileptic seizures.
U težim slučajevima mogu se pojaviti sljedeći simptomi: nerealnost, depersonalizacija, hiperakuzija, obamrlost i trnci u ekstremitetima, preosjetljivost na svjetlo, buku i fizički kontakt, halucinacije ili epileptički napadaji.
In severe cases, deficiency results in secondary hyperparathyroidism, hypophosphataemia, proximal muscle weakness and osteomalacia, further increasing the risk of falls and fractures in osteoporotic individuals.
U teškim slučajevima zbog nedostatka vitamina D dolazi do sekundarnoga hiperparatiroidizma, hipofosfatemije, slabljenja proksimalnih mišića i osteomalacije, čime se još više povećava rizik od padova i prijeloma kostiju u osoba s osteoporozom.
In severe cases, you may experience very low blood pressure, feel faint, and experience breathing distress caused by narrowing of the airways, which could be life-threatening.
U teškim slučajevima možete imati vrlo nizak krvni tlak, osjećaj da ćete se onesvijestiti i probleme s disanjem uzrokovane suženjem dišnih putova, što može biti opasno po život.
in severe chronic neutropenia patients
kod teških bolesnika s kroničnom neutropenijom
In severe chronic neutropenia patients
U bolesnika s teškom kroničnom neutropenijom
In severe hepatically impaired patients (Child-Pugh classification C), mean values for sirolimus AUC and t1/2 were increased 210% and 170% respectively, and CL/F was decreased by 67% compared to normal healthy subjects.
U bolesnika s teškim oštećenjem jetre (Child – Pughova klasifikacija C) srednja vrijednost za AUC sirolimusa bila je povećana 210%, t1/2 je bio povećan 170%, a CL/F je bio smanjen za 67% u usporedbi s zdravim pojedincima.
In severe hepatically impaired patients (Child-Pugh classification C), mean values for sirolimus AUC and t1/2 were increased 210% and 170%, respectively, and CL/F was decreased by 67% compared to normal healthy subjects.
U bolesnika s teškim oštećenjem jetre (Child – Pughova klasifikacija C) srednja vrijednost za AUC sirolimusa bila je povećana 210%, t½ je bio povećan 170%, a CL/F je bio smanjen za 67% u usporedbi s zdravim pojedincima.
In severe hepatically impaired patients (Child-Pugh classification C), mean values for sirolimus AUC and t1/2 were increased 210% and 170%, respectively, and CL/F was decreased by 67% compared to normal healthy subjects.
U bolesnika s teškim oštećenjem jetre (Child –Pughova klasifikacija C) srednja vrijednost za AUC sirolimusa bila je povećana 210%, t½ je bio povećan 170%, a CL/F je bio smanjen za 67% u usporedbi s zdravim pojedincima.
In severe kidney disease, the usual starting dose is just 1 Pramipexole Accord tablet 0.088 mg a day.
Kod teške bolesti bubrega, uobičajena početna doza je samo 1 tableta Pramipeksol Accord 0,088 mg dnevno.
In severe kidney disease, the usual starting dose is just 1 tablet Oprymea 0.088 mg a day.
Kod teške bolesti bubrega, uobičajena početna doza je samo 1 tableta Oprymea 0,088 mg dnevno.
In severe kidney disease, the usual starting dose is just 1 tablet Pramipexole Teva 0.088 mg a day.
Kod teške bolesti bubrega, uobičajena početna doza je samo 1 tableta Pramipeksol Teva 0,088 mg dnevno.
In severe renal impairment (creatinine clearance < 30 ml/min), plasma clearance is approximately 5 times lower than in normal renal function.
U bolesnika s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min), klirens iz plazme je oko 5 puta manji nego kod normalne bubrežne funkcije.
In severe renal impairment (creatinine clearance <30 ml/min), plasma clearance is approximately 5 times lower than in normal renal function.
U bolesnika s teškim oštećenjem bubrega (klirens kreatinina <30 ml/min), klirens iz plazme je oko 5 puta manji nego kod normalne bubrežne funkcije.
In severe renal insufficiency and end stage renal disease (creatinine clearance < 30 mL/min), mean plasma clearance declined by 70% and 75%, respectively.
Kod teške insuficijencije bubrega i završne faze bubrežne bolesti (klirens kreatinina < 30 ml/min), prosječan klirens kreatinina bio je manji za 70% odnosno 75%.
In severe renal insufficiency and end stage renal disease (creatinine clearance < 30 mL/min), mean plasma clearance declined by 70% and 75%, respectively.
Kod teške insuficijencije bubrega i završne faze bubrežne bolesti (klirens kreatinina < 30 ml/min), srednji klirens kreatinina bio je manji za 70% odnosno 75%.
In severe rheumatoid arthritis not previously treated with methotrexate, RoActemra given by infusion has been investigated in one main study involving 1,162 patients.
U slučaju ozbiljnog reumatoidnog artritisa koji se prije toga nije liječio metotreksatom, lijek RoActemra primijenjen u obliku infuzije ispitan je u glavnom ispitivanju koje je obuhvatilo 1 162 bolesnika.
In severely depressed patients (baseline MADRS total score ≥30) and in depressed patients with a high level of anxiety symptoms (baseline HAM-A total score ≥20) vortioxetine also demonstrated efficacy in the short-term studies in adults (the overall mean difference to placebo in MADRS total score at Week 6/8 ranged from 2.8 to 7.3 points and from 3.6 to 7.3 points, respectively, (MMRM analysis)).
U teško depresivnih bolesnika (početna vrijednost MADRS ukupni rezulatat ≥30) te u depresivnih bolesnika s visokom razinom simptoma anksioznosti (početna vrijednost HAM-A ukupni rezultat ≥20 vortioksetin je, također, pokazao djelotvornost u kratkoročnim ispitivanjima u odraslih (ukupna srednja razlika od placeba u ukupnom rezultatu na MADRS u 6/8 tjednu se kretala od 2,8 do 7,3 boda, odnosno 3,6 do 7,3 boda (MMRM analiza)).
In severely depressed patients (baseline MADRS total score ≥30) and in depressed patients with a high level of anxiety symptoms (baseline HAM-A total score ≥20) vortioxetine also demonstrated efficacy in the short-term studies in adults (the overall mean difference to placebo in MADRS total score at Week 6/8 ranged from 2.8 to 7.3 points and from 3.6 to 7.3 points, respectively,(MMRM analysis)).
U teško depresivnih bolesnika (početna vrijednost MADRS ukupni rezulatat ≥30) te u depresivnih bolesnika s visokom razinom simptoma anksioznosti (početna vrijednost HAM-A ukupni rezultat ≥20) vortioksetin je, također, pokazao djelotvornost u kratkoročnim ispitivanjima u odraslih (ukupna srednja razlika od placeba u ukupnom rezultatu na MADRS u 6/8 tjednu se kretala od 2,8 do 7,3 boda, odnosno od 3,6 do 7,3 boda (MMRM analiza)).
In severely diseased pigs, if water intake is reduced, pigs should be treated with a suitable injectable veterinary medicinal product.
Ako je u teško oboljelih svinja smanjeni unos vode, svinje treba liječiti odgovarajućim veterinarsko- medicinskim proizvodom u obliku za injiciranje.
In sheep
U ovaca
in sheep following administration of a double dose followed by a single dose 5 weeks later and a third vaccination with a single dose 7 weeks after the second dose, in pigs following administration of a double dose followed by a single dose 3 weeks later and a third vaccination with a single dose 7 weeks after the second dose.
u ovaca nakon primjene dvostruke doze, nakon koje je uslijedila jedna doza 5 tjedana kasnije i treće cijepljenje jednom dozom 7 tjedana nakon druge doze, u svinja nakon primjene dvostruke doze, nakon koje je uslijedila jedna doza 3 tjedna kasnije i treće cijepljenje jednom dozom 7 tjedana nakon druge doze.
In sheep transient signs of discomfort (head shaking, rubbing injection site, backing away) are very common after intramuscular injection.
Nakon intramuskularne primjene u ovaca vrlo su učestali sljedeći znakovi nelagode koji su prolazni (tresenje glavom, trljanje mjesta injiciranja, povlačenje u sebe .
In sheep, swellings may still be palpable after six weeks.
U ovaca, otekline još uvijek mogu biti opipljive i nakon šest tjedana.
In sheep, the pharmacokinetic profile of tulathromycin, when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, achieved a maximum plasma concentration (Cmax) of 1.19 µg/ml in approximately 15 minutes (Tmax) post-dosing and had an elimination half-life (t1/2) of 69.7 hours.
U ovaca, farmakokinetički profil tulatromicina primijenjenog u 1 dozi od 2,5 mg/kg t.m. intramuskularnim putem, maksimalnu koncentraciju u plazmi (Cmax) od 1,19 µg/ml postiže unutar 15 minuta (Tmax) nakon doziranja, te mu eliminacijski polu-život (t 1/2) iznosi 69,7 h.
In sheep, the pharmacokinetic profile of tulathromycin, when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, achieved a maximum plasma concentration (Cmax) of 1.19 µg/ml in approximately 15 minutes (Tmax) post-dosing and had an elimination half-life (t1/2) of 69.7 hours.
U ovaca, farmakokinetički profil tulatromicina primjenjenog u 1 dozi od 2,5 mg/kg t.m. intramuskularnim putem, maksimalnu koncentraciju u plazmi od 1,19 µg/ml postiže unutar 15 minuta (Tmax) nakon doziranja, te mu eliminacijski polu-život (t 1/2) iznosi 69,7 h.
In sheep, transient signs of discomfort (head shaking, rubbing injection site, backing away) are very common after intramuscular injection.
Nakon intramuskularne primjene u ovaca vrlo su učestali sljedeći znakovi nelagode koji su prolazni (tresenje glavom, trljanje mjesta injiciranja, povlačenje u sebe).
In SHEPHERD study, 96 of the 97 enrolled patients completed the study (one patient died following a thrombotic event).
U ispitivanju SHEPHERD, 96 od 97 uključenih bolesnika završilo je ispitivanje (jedan je bolesnik umro nakon trombotičkog incidenta).
In short term studies in rats,memantine like other NMDA-antagonists have induced neuronal vacuolisation and necrosis (Olney lesions) only after doses leading to very high peak serum concentrations.
U kratkoročnim ispitivanjima na štakorima, memantin je, kao i drugi NMDA-antagonisti, uzrokovao neuronsku vakuolizaciju i nekrozu (Olney lezije) samo nakon doza koje su dovodile do vrlo visokih vršnih serumskih koncentracija.
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased.
U ispitivanjima s jednokratnom dozom primjenjenom na dobrovoljcima, pri dozama do 800 mg, nuspojave su bile slične onima uočenim pri nižim dozama, međutim stope incidencije i težina bile su povećane.
In single dose, parallel group bioavailability studies (studies 1100.1517 and 1100.1531), the Viramune 50 and 100 mg prolonged-release tablets exhibited extended release characteristics of prolonged absorption and lower maximal concentrations, similar to the findings when a 400 mg prolonged- release tablet was compared to the Viramune immediate-release 200 mg tablet.
U ispitivanju bioraspoloživosti s jednokratnom dozom na paralelnim skupinama (ispitivanja 1100.1517 i 1100.1531), Viramune 50 i 100 mg tablete s produljenim oslobađanjem pokazale su svojstva produljene apsorpcije u skladu s produljenim oslobađanjem, kao i niže maksimalne koncentracije, što je slično otkrićima kada su 400 mg tablete s produljenim oslobađanjem uspoređivane s Viramune 200 mg tabletama s trenutnim oslobađanjem.
In SINGLE, 833 patients were treated with dolutegravir 50 mg once daily plus fixed-dose abacavir- lamivudine (DTG + ABC/3TC) or fixed-dose efavirenz-tenofovir-emtricitabine (EFV/TDF/FTC).
U ispitivanju SINGLE, 833 bolesnika liječena su ili dolutegravirom u dozi od 50 mg jedanput na dan u kombinaciji s fiksnom dozom abakavira-lamivudina (DTG + ABC/3TC) ili fiksnom dozom efavirenza-tenofovira-emtricitabina (EFV/TDF/FTC).
In SINGLE, 833 subjects were randomized and received at least one dose of either dolutegravir 50 mg once daily with fixed-dose abacavir-lamivudine (DTG + ABC/3TC) or fixed-dose efavirenz-tenofovir- emtricitabine (EFV/TDF/FTC).
U ispitivanju SINGLE 833 ispitanika randomizirano je u skupinu koja je primila najmanje jednu dozu dolutegravira od 50 mg jedanput na dan u kombinaciji s fiksnom dozom abakavira-lamivudina (DTG + ABC/3TC) ili fiksnu dozu efavirenza-tenofovira-emtricitabina (EFV/TDF/FTC).
In SINGLE, dolutegravir + ABC/3TC was still superior to EFV/TDF/FTC (viral suppression in 80% vs 72%, treatment difference 8.0% (2.3, 13.8), p=0.006, and with an adjusted mean change in CD4 count of 325 vs 281 cells/ mm3, respectively.
U ispitivanju SINGLE, kombinacija dolutegravir + ABC/3TC i dalje je bila superiorna u odnosu na EFV/TDF/FTC (virusna supresija postignuta je u 80% naspram 72% bolesnika), uz razliku između liječenja od 8,0% (2,3; 13,8), p=0,006 i s prilagođenom srednjom promjenom broja CD4 stanica od 325 stanica/mm3 (dolutegravir + ABC/3TC) naspram 281 stanice/mm3 (EFV/TDF/FTC).
In single-dose pharmacokinetic (PK) studies in young healthy subjects no relevant active substance- active substance interaction of memantine with glyburide/metformin or donepezil was observed.
U farmakokinetičkim ispitivanjima (PK) u kojima su primijenjene pojedinačne doze kod mladih zdravih ispitanika nije uočena značajna interakcija djelatna tvar-djelatna tvar između memantina i gliburida/metformina ili donepezila.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance – active substance interaction of memantine with glyburide/metformin or donepezil was observed.
U farmakokinetičkim ispitivanjima (PK) u kojima su primijenjene pojedinačne doze kod mladih zdravih ispitanika nije uočena značajna interakcija djelatna tvar-djelatna tvar između memantina i gliburida/metformina ili donepezila.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance- active substance interaction of memantine with glyburide/metformin or donepezil was observed.
U farmakokinetičkim ispitivanjima (PK) u kojima su primijenjene pojedinačne doze kod mladih zdravih ispitanika nije uočena značajna interakcija djelatna tvar-djelatna tvar između memantina i gliburida/metformina ili donepezila.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance- active substance interaction of memantine with glyburide/metformin or donepezil was observed.
U farmakokinetičkim ispitivanjima (PK) u kojima su primijenjene pojedinačne doze kod mladih zdravih ispitanika nije uočena značajna interakcija djelatna tvar-djelatna tvar memantina s gliburidom/metforminom ili donepezilom.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance-active substance interaction of memantine with glyburide/metformin or donepezil was observed.
U farmakokinetičkim ispitivanjima (PK) u kojima su primijenjene pojedinačne doze kod mladih zdravih ispitanika nije uočena značajna interakcija djelatna tvar-djelatna tvar memantina s gliburidom/metforminom ili donepezilom.
In situations when the body is exposed to excessive physical and/or mental stress, patients may need additional substitution of immediate release hydrocortisone tablets especially in the afternoon/evening, see also section ‘Use in intercurrent illness’ where other ways of temporarily increasing the dose of hydrocortisone is described.
U situacijama u kojima je tijelo izloženo prekomjernom fizičkom i/ili psihičkom stresu, bolesnicima može biti potrebna dodatna zamjenska tableta hidrokortizona s neposrednim/trenutnim oslobađanjem osobito poslije podne/uvečer, vidjeti također dio 'Primjena u slučaju istovremene bolesti' gdje su opisani drugi načini privremenog povećanja doze hidrokortizona.
In situations where a booster dose of both hepatitis A and hepatitis B are desired, Twinrix Adult can be given.
U slučaju da je potrebno docjepljivanje i protiv hepatitisa A i protiv hepatitisa B, može se dati Twinrix Adult.
In situations where a booster dose of both hepatitis A and hepatitis B are desired, Twinrix Paediatric can be given.
U slučaju da je potrebno docjepljivanje i protiv hepatitisa A i protiv hepatitisa B može se dati Twinrix Paediatric.
In situations where a booster dose of hepatitis A and/or hepatitis B is desired, a monovalent or combined vaccine can be given.
U slučaju kada je potrebno docjepljivanje protiv hepatitisa A i/ili hepatitisa B, mogu se primijeniti monovalentno ili kombinirano cjepivo.
In situations where a booster dose of hepatitis A and/or hepatitis B is desired, a monovalent or combined vaccine can be given.
U slučaju kada je potrebno docjepljivanje protiv hepatitisa A i/ili hepatitisa B, može se dati monovalentno ili kombinirano cjepivo.
In situations where the venipuncture set provided cannot be used (e.g. when infusing into a peripheral or central line), a separate filter compatible with Kovaltry should be used.
U situacijama kada se priloženi set za venepunkciju ne može uporabiti (npr. kad se infuzija daje u periferni ili centralni venski put), potrebno je uporabiti zaseban filter kompatibilan s lijekom Kovaltry.
In situations where very high maternally derived antibody levels are expected, the vaccination protocol should be planned accordingly.
U slučajevima kada se očekuje posebno visoka razina majčinskih protutijela protokol cijepljenja treba biti posebno planiran
In six Phase 2 and Phase 3 clinical trials, 1588 adult patients were treated with Zavicefta.
U šest kliničkih ispitivanja faze 2 i faze 3, 1588 odraslih bolesnika bilo je liječeno lijekom Zavicefta.
In sJIA and pJIA patients, ALT and AST levels should be monitored at the time of the second infusion and thereafter according to good clinical practice, see section 4.2.
Kod bolesnika sa sJIA i pJIA razine ALT-a i AST-a treba pratiti tijekom druge infuzije, a nakon toga u skladu s dobrom kliničkom praksom, vidjeti dio 4.2.
In sJIA patients, the central volume of distribution was 35 ml/kg and the peripheral volume of distribution was 60 ml/kg resulting in a volume of distribution at a steady state of 95 ml/kg.
Kod bolesnika sa sJIA centralni je volumen distribucije bio 35 ml/kg, a periferni volumen distribucije 60 ml/kg, što je rezultiralo volumenom distribucije u stanju dinamičke ravnoteže od 95 ml/kg.
In SJIA, Ilaris has been studied in two main studies.
U slučaju SJIA-e Ilaris je ispitan u dva glavna ispitivanja.
In SJIA, the first study showed that Ilaris was more effective than placebo at reducing symptoms of arthritis: around 84% of patients who received Ilaris achieved the required reduction in symptoms (36 out of 43), compared with about 10% of patients who received placebo (4 out of 41).
U slučaju SJIA-a, prvo je ispitivanje pokazalo da je lijek Ilaris djelotvorniji od placeba u ublažavanju simptoma artritisa: otprilike 84 % (36 od 43) bolesnika koji su primali Ilaris postigli su potrebno smanjenje simptoma, u usporedbi s otprilike 10 % (4 od 41) bolesnika koji su primali placebo.
In SLE, some of these antibodies attack the body’s own cells and organs instead (autoantibodies).
U bolesnika sa SLE-om, neka od tih protutijela umjesto toga napadaju vlastite stanice tijela i organe (autoprotutijela).
In small children, this may be 4 to 6 times a day.
Kod male djece to može biti 4 do 6 puta dnevno.